Kidney Transplant Rejection Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight's 'Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of kidney transplant rejection, historical and forecasted epidemiology, as well as the kidney transplant rejection therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Kidney Transplant Rejection Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Kidney Transplant Rejection Market Size
Key Takeaways from the Kidney Transplant Rejection Market Report
In June 2025, Biogen announced a clinical trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR.
In June 2025, Tract Therapeutics Inc. organized a Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients.
In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number expected to rise by 2034.
According to DelveInsight's estimates, there were approximately 27 thousand incident cases of kidney transplants across the US in 2023, with the number expected to rise by 2034.
In 2023, the US reported approximately 2 thousand acute and 8 thousand chronic cases of kidney transplant rejection, with these numbers expected to increase by 2034.
In 2023, among EU4 and the UK, the UK reported the highest number of living kidney transplants, with approximately 46 thousand instances, followed by France, with nearly 45 thousand cases. In contrast, Italy recorded the lowest, with around 28 thousand cases.
In 2023, EU4 and the UK reported approximately 2 thousand acute and 4 thousand chronic cases of kidney transplant rejection. By 2034, these numbers are expected to increase to nearly 4 thousand acute cases and 7 thousand chronic cases.
In 2023, Japan had approximately 2 thousand incident cases of kidney transplants. This number is projected to rise by 2034, growing at a CAGR of 0.7%.
The leading Kidney Transplant Rejection Companies such as Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others.
Promising Kidney Transplant Rejection Pipeline Therapies such as Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others.
Stay ahead in the competitive landscape of the Kidney Transplant Rejection Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Kidney Transplant Rejection Treatment Market Size
Kidney Transplant Rejection Epidemiology Segmentation in the 7MM
Total Kidney Transplant Rejection Incident Cases
Total Kidney Transplant Rejection Living Cases
Kidney Transplant Rejection Type-specific Cases
Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Prevalence
Marketed Kidney Transplant Rejection Prophylaxis Drugs
MYHIBBIN: Azurity Pharmaceuticals
MYHIBBIN, developed by Azurity Pharmaceuticals, is the first ready-to-use mycophenolate mofetil (MMF) oral suspension approved for preventing organ rejection in patients aged 3 months and older who have received allogeneic kidney, heart, or liver transplants. Approved by the US FDA in May 2024, MYHIBBIN is intended for use in combination with other immunosuppressive therapies. The product works by inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo guanosine nucleotide synthesis pathway, leading to the suppression of T and B lymphocyte proliferation and cytokine production, which prevents graft rejection.
THYMOGLOBULIN: Sanofi
THYMOGLOBULIN, developed by Sanofi, is an immunosuppressive therapy derived from rabbit serum through immunization with human thymocytes. This purified, pasteurized IgG product targets T lymphocyte antigens and is designed for the prevention of acute kidney transplant rejection. Administered via intravenous infusion, it exerts therapeutic effects by clearing circulating T cells and modulating their activation, homing, and cytotoxic functions. Its mechanism includes targeting multiple T-cell markers, such as CD2, CD3, CD4, and HLA-DR, promoting immune suppression and reducing the risk of transplant rejection.
NULOJIX: Bristol Myers Squibb
NULOJIX (belatacept), developed by Bristol Myers Squibb, is a selective T-cell costimulation blocker approved for the prevention of organ rejection in adult kidney transplant recipients. Administered via intravenous infusion, NULOJIX is used alongside basiliximab induction, mycophenolate mofetil, and corticosteroids. Its mechanism of action involves targeting CD80 and CD86 on antigen-presenting cells, thereby preventing CD28-mediated T-cell activation, a key driver of immunologic rejection. This results in reduced T-cell proliferation and cytokine production, including interleukin-2 and TNF-a, mitigating the immune response in transplant rejection.
Emerging Kidney Transplant Rejection Drugs
MDR-101: Medeor Therapeutics
MDR-101, developed by Medeor Therapeutics, is an innovative cellular therapy derived from the blood and peripheral stem cells of a living kidney donor. The therapy is designed to induce donor-specific immune tolerance, effectively preventing kidney transplant rejection. By reprogramming the recipient's immune system to accept the donor organ, MDR-101 eliminates the need for lifelong immunosuppressive drugs and their associated side effects, thereby enhancing transplant kidney function and long-term survival. Positive interim data from a Phase III trial, presented as a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week in November 2023, highlighted its potential as a breakthrough in transplantation medicine. MDR-101 has received ODD in both the US and EU. The clinical trial is being conducted under an FDA Special Protocol Assessment (SPA). In September 2020, the US FDA also granted Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101 for the prevention of kidney transplant rejection. Further, in January 2018, the California Institute for Regenerative Medicine (CIRM) awarded USD 18.8 million to support the Phase III clinical trial under its clinical trial funding initiative.
Tegoprubart (AT-1501): Eledon Pharmaceuticals
Tegoprubart, developed by Eledon Pharmaceuticals, is a humanized monoclonal antibody targeting the CD40L pathway, designed to prevent kidney transplant rejection by blocking the CD40-CD40L interaction. This innovative immunosuppressive therapy aims to replace traditional calcineurin inhibitors (CNIs), such as tacrolimus, potentially improving long-term graft survival and patient outcomes. In September 2024, Eledon completed enrollment for the Phase II BESTOW trial, four months ahead of schedule, with topline results anticipated in Q4 2025. Phase Ib trial data presented at the American Transplant Congress (ATC) in June 2024 demonstrated the drug's safety and tolerability.
Riliprubart (BIVV020, SAR445088): Sanofi
Riliprubart, developed by Sanofi, is an IgG4 humanized monoclonal antibody under investigation for the treatment of Antibody-Mediated Rejection (AMR) in kidney transplants. The drug works by selectively inhibiting activated complement component C1s, a critical mediator of the inflammatory processes associated with AMR. Phase II clinical trials are currently underway to evaluate the efficacy and safety of Riliprubart in patients diagnosed with or at risk of AMR. Administered intravenously, Riliprubart represents a promising therapeutic approach to addressing AMR in kidney transplant recipients.
Discover the future of Kidney Transplant Rejection Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Kidney Transplant Rejection Market Drivers and Barriers
Kidney Transplant Rejection Market Outlook
Kidney transplant rejection is a major concern for recipients, as it can severely affect the long-term success and function of the transplanted organ. Rejection happens when the recipient's immune system recognizes the donor kidney as foreign, prompting an immune response that damages the graft. There are two main types of rejection: Acute, which usually occurs within the first-year after transplantation, and chronic, which develops gradually over several years and is more prevalent. Chronic rejection is often associated with insufficient immunosuppression or non-compliance with medication regimens, leading to ongoing immune attacks that result in scarring and eventual loss of kidney function. Around 15–20% of transplant recipients experience some form of rejection, highlighting the importance of regular monitoring and strict adherence to immunosuppressive therapy to reduce this risk.
Kidney Transplant Rejection Drugs Market Insights
Currently, a variety of medication approaches for kidney transplant rejection prophylaxis involve approved treatments that utilize different mechanisms of action to support long-term transplant success. These include ENVARSUS XR, IDEFIRIX, NULOJIX, THYMOGLOBULIN, MYHIBBIN, and SIMULECT, among others, all of which play a crucial role in managing immune responses and minimizing the risk of rejection. Kidney transplant rejection aims to manage immune responses, prevent further organ damage, and ensure long-term transplant success. Treatment involves a combination of immunosuppressive therapies, close monitoring, and supportive care to address acute and chronic rejection. Key goals include preserving graft function, reducing inflammation, minimizing complications, and improving the patient's quality of life. Lifestyle adjustments, including dietary management and adherence to medication regimens, are essential for long-term success. While challenges remain, ongoing research is focused on advancing therapies to enhance graft survival and improve outcomes for transplant recipients.
Explore the dynamics of the Kidney Transplant Rejection Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Kidney Transplant Rejection Ongoing Clinical Trials Analysis
Scope of the Kidney Transplant Rejection Market Report
Coverage- 7MM
Study Period- 2020-2034
Kidney Transplant Rejection Companies- Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others.
Kidney Transplant Rejection Pipeline Therapies- Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others.
Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection Current Marketed and Kidney Transplant Rejection Emerging Therapies
Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers
Kidney Transplant Rejection Unmet Needs, KOL's views, Analyst's views, Kidney Transplant Rejection Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Kidney Transplant Rejection – 7MM Market Analysis
13. KOL Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why Nektar Therapeutics Stock Was Red-Hot Today
The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering excellent news from the lab, the company's shares leaped 19% higher on a significant analyst price target change. A clear buy, says analyst Well before market open, H.C. Wainwright's Arthur He poured some rocket fuel into his Nektar price target, setting it anew at $120 per share. That's far above his previous level, which was a mere $6.50. In making the change, he left his buy recommendation intact. In what's hardly a surprising development, He's adjustment was due to the positive results in the latest completed clinical trial for Nektar's eczema drug rezpegaldesleukin. The study put the medicine through its paces for the treatment of moderate-to-severe atopic dermatitis (AD), a form of eczema. In the analyst's view, it did well enough to become a top drug in the treatment of the affliction. On Tuesday, the biotech announced, no doubt with immense satisfaction, that rezpegaldesleukin met all of its primary and secondary endpoints in the phase 2b trial. After 16 weeks of treatment with the subcutaneous drug, patients demonstrated a 53% to 61% improvement in symptoms when measured with an eczema index. This compared very favorably to 31% for patients taking a placebo. Vast potential This easily makes Nektar's drug the success of the week in the biotech world. As pointed out by He, Rezpegaldesleukin clearly has potential to treat the many people who suffer from AD. As such, the progress of the drug -- and its developer -- will be exciting to watch going forward. Should you invest $1,000 in Nektar Therapeutics right now? Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor 's total average return is809% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Dental Services In Calabasas Now Offered at Oaks Dental
Residents of Calabasas and surrounding communities will soon have access to exceptional dental care as Oaks Dental announces its grand opening on July 7th, 2025. The state-of-the-art dental practice, led by distinguished dentists Dr. Kourosh Keihani and Dr. Tariq Jabaiti, is now accepting appointments, bringing comprehensive dental services to the Calabasas area. Located in the heart of Calabasas, Oaks Dental combines advanced dental technology with personalized patient care to deliver exceptional dental treatments. The practice offers a full range of services including cosmetic dentistry, restorative procedures, and preventive care, all designed to help patients achieve optimal oral health and beautiful smiles. The new Calabasas dental practice features modern facilities equipped with cutting-edge technology to ensure patients receive the highest standard of care. From digital imaging systems to laser dentistry tools, Oaks Dental has invested in advanced equipment that enhances diagnostic accuracy and treatment outcomes while maximizing patient comfort. Dr. Kourosh Keihani, a premier cosmetic and restorative dentist, brings his meticulous attention to detail and commitment to exceptional care to the Calabasas community. Known for combining advanced clinical expertise with refined artistry, Dr. Keihani creates natural, beautiful smiles through techniques including digital smile design, minimally invasive procedures, and full-mouth rehabilitation. "We are thrilled to bring our dental expertise to Calabasas and establish relationships with members of this wonderful community," said Dr. Tariq Jabaiti. "Our mission at Oaks Dental is to provide comprehensive dental care in a comfortable environment where patients feel valued and respected. We believe everyone deserves access to high-quality dental services that enhance both oral health and overall wellbeing." Comprehensive Dental Implant Solutions Oaks Dental recognizes the significant impact missing teeth can have on confidence, oral functionality, and quality of life. The practice offers advanced dental implant solutions designed to restore smiles, enhance chewing function, and prevent bone loss. Their dental implant procedures provide durable, natural-looking replacements for missing teeth, helping patients regain confidence in their smiles. Advanced Veneer Treatments The cosmetic dentistry team at Oaks Dental specializes in veneer treatments that transform smiles. These thin porcelain shells are custom-crafted to cover the front surface of teeth, addressing issues such as discoloration, chips, gaps, and minor misalignments. The practice employs precise techniques to ensure veneers blend seamlessly with natural teeth, creating radiant smiles that enhance facial aesthetics. Innovative Invisalign Services Oaks Dental provides Invisalign treatment. This modern orthodontic solution uses clear, removable aligners to gradually shift teeth into proper alignment. The Calabasas dental practice offers comprehensive consultations to determine candidacy for Invisalign and develops personalized treatment plans to achieve optimal results. Professional Teeth Whitening Procedures Oaks Dental delivers professional teeth whitening services that brighten smiles effectively and safely. Their whitening treatments are significantly more powerful than over-the-counter options, producing dramatic results while protecting tooth enamel and gum tissue. Patients can choose between in-office whitening for immediate results or take-home kits for gradual improvement. Emergency Dental Care Oaks Dental provides emergency dental services for unexpected issues such as severe toothaches, broken teeth, lost fillings, or damaged restorations. The practice maintains flexibility in their schedule to accommodate urgent cases, ensuring patients receive timely relief from pain and appropriate treatment to prevent further complications. Both Dr. Keihani and Dr. Jabaiti bring impressive credentials to the Calabasas dental community. Dr. Jabaiti earned his Doctor of Dental Surgery at the Herman Ostrow School of Dentistry at USC and currently holds a faculty professor position there. He maintains affiliations with prestigious organizations including the California Dental Association, American Dental Association, American Academy of Cosmetic Dentistry, and the Ventura County Dental Association. The grand opening celebration on July 7th will welcome community members to meet the dental team, and learn about the comprehensive services available. The practice is currently scheduling appointments for new patients seeking general dental care, cosmetic procedures, and specialized treatments. For more information please contact Dr. Tariq Jabaiti at About Oaks Dental Oaks Dental is a premier dental practice in Calabasas offering comprehensive dental services including veneers, dental implants, Invisalign, dental crowns, tooth extraction, emergency dental care, root canal treatment, and teeth whitening. Led by Dr. Kourosh Keihani and Dr. Tariq Jabaiti, the practice combines advanced technology with personalized care to deliver exceptional dental experiences. The team is committed to helping patients achieve healthy, beautiful smiles through preventive, restorative, and cosmetic dental solutions. Media Contact Company Name: Oaks Dental Contact Person: Dr. Tariq Jabaiti Email: Send Email Phone: (818) 431-2000 Address: 5000 Parkway Calabasas Suite 308 City: Calabasas State: CA Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Dreame Adds Intelligent Air Purification to Its Smart Home Line-Up with All-New AirPursue Adaptive Purifiers
Advanced Tracking Technology and Precision Detection Create Personalized Air Quality Solutions for Everyone to Combat Airborne Allergens, Viruses and More. Dreame Technology, a smart home appliance company renowned for its ecosystem of innovative solutions, today introduced the AirPursue PM20 Adaptive Air Purifier — its debut offering for intelligent air purification technology. The meticulously engineered AirPursue PM20 redefines air quality management with innovative human tracking capabilities and precision detection systems, delivering personalized air purification that adapts to every need. First unveiled at CES 2025, the Dreame PM20 has been recognized by Frost & Sullivan as "The World's First AI-Powered and Tracking Air Purifier" and "The World's First Smart Dual-Flow Air Purifier," following comprehensive research of the global air purifier market. Allergy season is hitting Americans harder than ever before, as the pollen season now lasts approximately three weeks longer than it did 50 years ago, and plants and trees produce about 20% more pollen. Additionally, the CDC reported a staggering 60 million Americans — 1 in 3 adults and 1 in 4 children — suffer from seasonal allergies. With longer, more intense allergy seasons becoming the new normal, high-quality air filtration has become essential for many households. "Dreame's cutting-edge technology is revolutionizing how consumers experience clean and healthy homes and with the AirPursue PM20, we're helping reduce airborne viruses and contaminants through our market-leading air filtration," said Ana Wang, General Manager of Dreame Technology North America. "With summer allergies worse than ever, intelligent air purification is essential for consumers, and the PM20 understands and responds to user behavior, allowing people to live their healthier lives." Adaptive Intelligence That Follows Your Every Move The AirPursue PM20 provides pristine air quality without constant manual adjustments through advanced radar technology with precision sensors to create a truly personalized air purification experience. Key features of the AirPursue PM20 include: 1. Human Tracking by Radar Technology — The Enviro Detect Tech system uses intelligent induction power to automatically detect a human presence, delivering dynamic wind adjustment within a 5-meter (16.4 ft) range through 120° coverage, ensuring clean air follows you wherever you go in the room. 2. Dualflow Modulation Technology — Advanced Dualflow Modulation technology provides balanced comfort in hot climates and ventilated spaces, functioning as an air purifier or circulating fan with comprehensive 100m² (1076 ft²) space coverage. The large airflow outlet delivers 400 m³/h of clean air, enhancing the efficiency of the air purifier. 3. Advanced Filtration and Elimination System — A 4-Layer Filtration System helps prevent respiratory infections and reduces allergy symptoms by tackling 14 air pollutants and removing nine types of common bacteria and viruses. 4. Precision Detection with 7 Sensors — An advanced sensor array accurately measures air quality, while an LCD screen shows precise levels of allergens, formaldehyde, TVOC, and other contaminants. 5. Smart Control and Connectivity — The AirPursue PM20 features three operating modes with remote app control through the intuitive Dreamehome App and built-in intelligent voice assistance. Complete AirPursue Series for Every Home Dreame offers two models in the AirPursue series to meet diverse household needs: 1. AirPursue PM20 — The flagship model, priced at $999.99, features a high Clean Air Delivery Rate (CADR) of 400 m³/h, making it ideal for larger spaces. 2. AirPursue PM10 — The essential model, priced at $899.99, offers a CADR of 300 m³/h, providing efficient purification for medium-sized rooms. Both models feature a 100m² (1076 ft²)* uniform purification area, 10-meter (32.8 ft)* air projection distance, P4/F4 dust containment class rating, 2-year filter life, H13 HEPA rating and whisper-quiet operation. Each purifier achieves a 99.97%* particle removal rate and includes eight precision sensors, formaldehyde decomposition, remote control and an LCD screen. *All data are based on Dreame in-house lab tests. Availability and Pricing The Dreame AirPursue PM20 and PM10 are now available in both the U.S. and Canadian markets through Dreame's official website and Amazon store. From now until July 8, U.S. customers can pre-order the PM20 at a special price of $749.99 and the PM10 at a price of $699.99 on Dreame's official website, and receive a complimentary Carbon Filter Bundle. In Canada, where the regular price for the PM10 and PM20 is $1099.99 and $1,199.99 respectively, customers can use the code PMDREAME to access early bird pricing — $699.99 for the PM10 and $769.99 for the PM20. About Dreame Technology Established in 2017, Dreame Technology is an innovative consumer product company focused on smart home cleaning appliances with the vision to empower lives through technology. For more information, please visit Media Contact Company Name: Dreame Technology Contact Person: Cissy Cai Email: Send Email Country: United States Website:
